Reviva Pharmaceuticals Holdings (RVPH) executive compensation, 2025 proxy

Laxminarayan Bhat, PhD, Chief Executive Officer and President, was paid $607,500 in 2024, down 78% from $2.8M the year before.

Filed
November 4, 2025
Annual meeting
December 18, 2025
Pay year
2024
Named executives
2
CEO total pay
$607,500-78% vs prior year
CEO 2025 base salary
$565,000Effective January 1, 2025
CFO 2025 base salary
$330,000Effective January 1, 2025
CEO 2025 option grant
519,000 sharesGranted February 2025
CFO 2025 option grant
194,250 sharesGranted February 2025
CEO target bonus
50%2025 target level
CFO target bonus
41%2025 target level

How PhD was paid

$607,500 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary74%Bonus26%

Named executive officers

ExecutiveTotal
Laxminarayan Bhat, PhDChief Executive Officer and President$607,500
Narayan PrabhuChief Financial Officer$404,950

What changed and why

  • $608K$607,500 was CEO total compensation in 2024, down from $2,764,747 in 2023 because 2024 included no option award.
  • $158K$157,500 was the CEO's 2024 cash bonus, while the CFO received $79,950.
  • $565K$565,000 became the CEO's 2025 base salary, retroactive to January 1, 2025.
  • $1.80519,000 CEO and 194,250 CFO option shares were granted in February 2025 at a $1.80 exercise price.
  • 50%50% of base salary was the CEO's 2025 target bonus; the CFO's target was 41%.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.